Tvardi Therapeutics, Inc.
Clinical-stage biopharma developing oral STAT3 inhibitors for cancer and fibrosis.
TVRD | IL
Overview
Corporate Details
- ISIN(s):
- US1407553072 (+1 more)
- LEI:
- 549300COVOY41P0GZ881
- Country:
- United States of America
- Address:
- 3 SUGAR CREEK CTR. BLVD., 77478 SUGAR LAND
- Website:
- https://tvarditherapeutics.com
- Sector:
- Manufacturing
Description
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered, small molecule therapies. The company's core approach is targeting STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi's therapeutic pipeline is designed to address conditions with significant unmet medical needs, including various forms of cancer and fibrosis-driven diseases. Its clinical trials are evaluating potential treatments for indications such as liver cancer and idiopathic pulmonary fibrosis (IPF).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tvardi Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tvardi Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tvardi Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
